Imsidolimab

Summary

Imsidolimab (CHEMBL4650441) is a phase-3 clinical-stage antibody; indicated across 6 conditions including acneiform dermatitis and ichthyosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 6 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650441
Name	Imsidolimab
Type	Antibody
Max phase	3

Also known as: ANB-019, Anb019, ANB019, Imsidolimab, IMSIDOLIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acneiform dermatitis	2	MONDO:0006521	EFO:1000662
ichthyosis	2	MONDO:0019269	MONDO:0019269
acne	2	MONDO:0011438	EFO:0003894
hidradenitis suppurativa	2	MONDO:0006559	EFO:1000710
psoriasis	2	MONDO:0005083	MONDO:0015597

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05352893	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
NCT05366855	PHASE3	TERMINATED	Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
NCT03619902	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
NCT03633396	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
NCT04697056	PHASE2	TERMINATED	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
NCT04697069	PHASE2	TERMINATED	A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
NCT04856917	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
NCT04856930	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).